Download PDF
Journal of Pediatric Epilepsy 2013; 02(04): 239-243
DOI: 10.3233/PEP-14068
Georg Thieme Verlag KG Stuttgart – New York

Serum and cerebrospinal fluid excitatory amino acid, nitric oxide and cerebrospinal fluid malondialdehyde levels in West syndrome

Sefer Kumandas
a   Department of Pediatric Neurology, Erciyes University, Kayseri, Turkey
,
Hatice G. Poyrazoglu
a   Department of Pediatric Neurology, Erciyes University, Kayseri, Turkey
,
Huseyin Per
a   Department of Pediatric Neurology, Erciyes University, Kayseri, Turkey
,
Tamer Kuyucu
b   Department of Pediatrics, Isparta Maternity and Children Diseases Hospital, Isparta, Turkey
,
Hakan Gumus
a   Department of Pediatric Neurology, Erciyes University, Kayseri, Turkey
,
Recep Saraymen
c   Department of Biochemistry, Erciyes University, Kayseri, Turkey
› Author Affiliations
Subject Editor:
Further Information

Publication History

04 December 2013

17 January 2014

Publication Date:
18 July 2015 (online)

Also available at
  PDF Download Buy Article Permissions and Reprints
Zoom Image

Abstract

West syndrome (WS) is an epileptic syndrome of early childhood. There have been a limited numbers of studies of cerebrospinal fluid (CSF) excitatory amino acid (EAA), nitric oxide (NO), and malondialdehyde (MDA) levels, as well as plasma levels of EAA, and NO, in WS. In this article, CSF EAA, NO, and MDA levels and plasma EAA, NO status, and a determination of the effects of antiepileptic drug therapy on these values were investigated in children with WS. Evaluation of CSF and serum EAA, NO, and MDA levels and of serum EAA and NO levels after 3 mo of antiepileptic drug therapy revealed a statistically significant decrease in CSF aspartate, glutamate, NO and MDA levels. In conclusion, the decrease in CSF MDA levels in this study is the result of both the decrease in glutamate activity and neuronal damage after controlling seizures with antiepileptic drugs.

Keywords

Excitatory amino acid - nitric oxide and malondialdehyde - West syndrome - treatment